{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:16:52Z","timestamp":1790709412872,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-024-03402-5","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:14:11Z","timestamp":1728486851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel"],"prefix":"10.1007","volume":"316","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7330-1627","authenticated-orcid":false,"given":"Megan H.","family":"Trager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6780-6506","authenticated-orcid":false,"given":"Alyce M.","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0747-2479","authenticated-orcid":false,"given":"Stephen W.","family":"Dusza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Geskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2452-8291","authenticated-orcid":false,"given":"Autumn","family":"Guyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2704-3855","authenticated-orcid":false,"given":"Nour","family":"Abuhadra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3600-3751","authenticated-orcid":false,"given":"Ayca","family":"Gucalp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4818-3710","authenticated-orcid":false,"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"3402_CR1","doi-asserted-by":"crossref","unstructured":"Kampan NC et al (2015) Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer. Biomed Res Int, 2015: p. 413076","DOI":"10.1155\/2015\/413076"},{"issue":"4","key":"3402_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jaip.2014.04.010","volume":"2","author":"A Banerji","year":"2014","unstructured":"Banerji A et al (2014) Management of hypersensitivity reactions to Carboplatin and Paclitaxel in an outpatient oncology infusion center: a 5-year review. J Allergy Clin Immunol Pract 2(4):428\u2013433","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"3402_CR3","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1111\/all.12350","volume":"69","author":"P Demoly","year":"2014","unstructured":"Demoly P et al (2014) International Consensus on drug allergy. Allergy 69(4):420\u2013437","journal-title":"Allergy"},{"issue":"1","key":"3402_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1200\/JCO.2000.18.1.102","volume":"18","author":"M Markman","year":"2000","unstructured":"Markman M et al (2000) Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J Clin Oncol 18(1):102\u2013105","journal-title":"J Clin Oncol"},{"issue":"4","key":"3402_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jaci.2015.10.039","volume":"137","author":"M Picard","year":"2016","unstructured":"Picard M et al (2016) Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 137(4):1154\u20131164e12","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3402_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000450748","volume":"62","author":"T Ratanajarusiri","year":"2017","unstructured":"Ratanajarusiri T et al (2017) A difference in the incidences of hypersensitivity reactions to original and generic taxanes. Chemotherapy 62(2):134\u2013139","journal-title":"Chemotherapy"},{"issue":"3","key":"3402_CR7","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1006\/gyno.2001.6546","volume":"84","author":"JS Kwon","year":"2002","unstructured":"Kwon JS et al (2002) A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 84(3):420\u2013425","journal-title":"Gynecol Oncol"},{"key":"3402_CR8","unstructured":"Gonz\u00e1lez-D\u00edaz SN et al (2022) Atopy, allergen sensitization and development of hypersensitivity reactions to paclitaxel. J Oncol Pharm Pract, : p. 10781552221080415, Epub 2022 Feb 21. PMID: 35188862."},{"issue":"4","key":"3402_CR9","doi-asserted-by":"publisher","first-page":"e00985","DOI":"10.1002\/prp2.985","volume":"10","author":"AI Haine","year":"2022","unstructured":"Haine AI et al (2022) Ranitidine and the incidence of hypersensitivity reactions to paclitaxel: a retrospective cohort study. Pharmacol Res Perspect 10(4):e00985","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"3402_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000336772","volume":"74","author":"E Piovano","year":"2012","unstructured":"Piovano E et al (2012) A search for predictive factors for hypersensitivity reactions to paclitaxel and platinum salts in chemotherapy for gynecologic pelvic neoplasms. Gynecol Obstet Invest 74(1):21\u201327","journal-title":"Gynecol Obstet Invest"},{"issue":"1","key":"3402_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00280-017-3332-7","volume":"80","author":"T Aoyama","year":"2017","unstructured":"Aoyama T et al (2017) Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? Cancer Chemother Pharmacol 80(1):65\u201369","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"3402_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","volume":"26","author":"V Sibaud","year":"2016","unstructured":"Sibaud V et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26(5):427\u2013443","journal-title":"Eur J Dermatol"},{"key":"3402_CR13","unstructured":"Chemicals A Cremophor EL. accessed 1\/6\/24; https:\/\/www.atamanchemicals.com\/cremophor-el_u28015\/"},{"key":"3402_CR14","first-page":"763","volume-title":"Meyler\u2019s Side effects of drugs (Sixteenth Edition)","author":"Cremophor","year":"2016","unstructured":"Cremophor (2016) Meyler\u2019s Side effects of drugs (Sixteenth Edition). Elsevier, Oxford, p 763. J.K. Aronson, Editor"},{"issue":"1","key":"3402_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s12094-019-02122-x","volume":"22","author":"A Parisi","year":"2020","unstructured":"Parisi A et al (2020) First-line carboplatin\/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clin Transl Oncol 22(1):158\u2013162","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"3402_CR16","first-page":"159","volume":"38","author":"O Idsoe","year":"1968","unstructured":"Idsoe O et al (1968) Nature and extent of penicillin side-reactions, with particular reference to fatalities from anaphylactic shock. Bull World Health Organ 38(2):159\u2013188","journal-title":"Bull World Health Organ"},{"issue":"4","key":"3402_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.iac.2017.07.004","volume":"37","author":"M Picard","year":"2017","unstructured":"Picard M (2017) Management of hypersensitivity reactions to Taxanes. Immunol Allergy Clin North Am 37(4):679\u2013693","journal-title":"Immunol Allergy Clin North Am"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-03402-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-03402-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T17:06:33Z","timestamp":1729875993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-03402-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-03402-5","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The most recent study modification was approved by the IRB at Memorial Sloan Kettering Cancer Center (IRB 16\u2013458) on 4\/22\/24.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr Mario Lacouture has the following disclosures novocure, Novartis, RBC\/LaRoche Posay, Lutris, OnQuality, Oncoderm, Apricity, Janssen (consulting); Lutris, OQL, Novartis, Paxman, Astrazeneca (Research). The remaining authors have no relevant conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"665"}}